Clinical trial DeLLphi 305
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination with Durvalumab vs Durvalumab Alone in Subjects with Extensive Stage Small Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi 305)
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Amgen |
| EudraCT Identifier | 2023-505989-29-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06211036 |
| Last update |